Popular culture tells us that many women lose interest in sex during or after menopausal transition, but those ageist and sexist messages aren’t supported by good scientific research. We want you to have the facts and offer a few helpful remedies.
Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.
FOR IMMEDIATE RELEASE Contact: Evita Almassi, [email protected] or (202) 682-6240
Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
